• Available

NCT05256446: AMG 701 Expanded Access Program

NCT05256446: AMG 701 Expanded Access Program


AMG701

AMG 701 Expanded Access Program


Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.


Sponsor

Amgen

 

ClinicalTrials.gov Identifier: NCT04998747

AMG 701 Expanded Access Program


First Posted: February 25, 2022


Click here for details on ClinicalTrials.gov

 

pavurutamab - anti-BCMA/CD3 BiTE antibody AMG 701

AMG 701

Pavurutamab (Code C147028)

AMG 701

AMG-701

AMG701

Anti-BCMA x Anti-CD3 BiTE AMG 701

Anti-BCMA/CD3 BiTE Antibody AMG 701

BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701

Bispecific T-cell Engager Antibody AMG 701

BiTE Antibody AMG 701

Pavurutamab

PAVURUTAMAB


Drug: AMG 701

 

Posts Archive